Amneal Pharmaceuticals

Amneal Pharmaceuticals launches CREXONT®, an extended-release carbidopa and levodopa capsule for Parkinson's disease, offering longer 'Good On' time and less frequent dosing. Available in U.S. pharmacies, with a $25 copay program for eligible patients. Amneal to present at the International Congress of Parkinson's Disease and Movement Disorders in 2024.

Rituximab, a monoclonal antibody, is crucial in treating cancers like NHL and CLL by targeting CD20 protein on abnormal lymphocytes, driving market growth. The United States Ritonavir Drug Market analysis includes market dynamics, technological advancements, and regional variations impacting the market.

The 'Migraine: Seven-Market Drug Forecast and Market Analysis' report, added to ResearchAndMarkets.com's offering, forecasts the migraine market in the US, France, Germany, Italy, Spain, the UK, and Japan to grow from $9.2 billion in 2023 to $16.4 billion by 2033, driven by a 6.0% CAGR. The report covers epidemiology, treatment options, unmet needs, pipeline analysis, and market competition.

In August 2024, the FDA made several decisions on new therapeutic agents, including approving Indapta Therapeutics’ g-NK cell therapy IDP-023 for progressive multiple sclerosis, Amneal Pharmaceuticals’ carbidopa/levodopa ER capsules IPX203 for Parkinson disease, and Medtronic’s deep brain stimulation technology for use during general anesthesia. The agency also granted fast track designation to Abata Therapeutics’ Treg therapy ABA-101 for progressive MS and [18F]PI-2620 tau-PET diagnostic for neurodegenerative diseases. Additionally, the FDA cleared Clearmind Biomedical’s Neuroblade System for minimally invasive neurosurgery and granted priority review to SpringWorks Therapeutics’ mirdametinib for neurofibromatosis type 1-associated plexiform neurofibromas.

FDA approves Boruzu, a ready-to-use bortezomib injectable for multiple myeloma and mantle cell lymphoma, developed by Shilpa Medicare Limited and to be commercialized by Amneal Pharmaceuticals, expected to launch by June 2025. Boruzu simplifies administration compared to Velcade, offering convenience for clinicians. Bortezomib, a proteasome inhibitor, targets 26S proteasomes, causing toxic protein accumulation and cancer cell death, with myeloma cells more susceptible. Common side effects include nausea, diarrhea, and nerve damage.

FDA approves Boruzu, a ready-to-use bortezomib injection for multiple myeloma and mantle cell lymphoma, reducing compounding steps. Developed by Amneal Pharmaceuticals and Shilpa Medicare, it is expected to launch in Q2 2025.

Amneal Pharmaceuticals and Shilpa Medicare announce FDA approval of BORUZU, a ready-to-use bortezomib injection for subcutaneous or IV administration, reducing preparation steps. Shilpa developed the molecule, and Amneal will manufacture and commercialize the product, expected to launch with a unique J-code in Q2 2025.

Amneal Pharmaceuticals and Shilpa Medicare receive FDA approval for Boruzu, a Velcade biosimilar for subcutaneous use. Boruzu simplifies administration, reducing preparation steps. Amneal plans to launch in Q2 2025 with a unique J-code. Common adverse reactions include asthenic conditions, diarrhoea, and nausea.

FDA approves Amneal Pharmaceuticals and Shilpa Medicare’s Boruzu, the first ready-to-use bortezomib for subcutaneous and intravenous administration, simplifying oncology treatment by eliminating preparation steps required with existing products like Velcade. Boruzu treats multiple myeloma and mantle cell lymphoma, with common adverse events including asthenic conditions, diarrhea, nausea, and more. The treatment is expected to launch in Q2 of next year.